



# A factor analysis approach to examining relationships among ovarian steroid concentrations, gonadotrophin concentrations and menstrual cycle length characteristics in healthy, cycling women

## Citation

Barrett, E. S., I. Thune, S. F. Lipson, A.- S. Furberg, and P. T. Ellison. 2013. "A Factor Analysis Approach to Examining Relationships Among Ovarian Steroid Concentrations, Gonadotrophin Concentrations and Menstrual Cycle Length Characteristics in Healthy, Cycling Women." *Human Reproduction* 28, no. 3: 801–811.

## Published Version

doi:10.1093/humrep/des429

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:12363918>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

## Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

**A factor analysis approach to examining relationships among ovarian steroid concentrations, gonadotropin concentrations, and menstrual cycle length characteristics in healthy, cycling women.**

Running title: Integration of menstrual function within cycles

E.S. Barrett<sup>1</sup>, I. Thune<sup>2,3</sup>, S.F. Lipson<sup>4</sup>, A.-S. Furberg<sup>2</sup>, P.T. Ellison<sup>4</sup>

1 Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, NY, 14534, United States.

2 Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway 9037.

3 The Cancer Center, Oslo University Hospital, Oslo, Norway 0424.

4 Department of Human Evolutionary Biology, Harvard University, Cambridge, MA, 02138, United States.

Corresponding author:

Emily S. Barrett, PhD

Department of Obstetrics and Gynecology

University of Rochester School of Medicine and Dentistry

601 Elmwood Avenue, Box 668

Rochester, NY 14642 UNITED STATES

Phone: (585)275-9187; Fax: (585)276-2171

Emily\_barrett@urmc.rochester.edu

41 **Abstract**

42 Title: A factor analysis approach to examining relationships among ovarian steroid  
43 concentrations, gonadotropin concentrations, and menstrual cycle length characteristics in  
44 healthy, cycling women.

45 Study question: How are ovarian steroid concentrations, gonadotropins, and menstrual cycle  
46 characteristics inter-related within normal menstrual cycles?

47 Summary answer: Within cycles, measures of estradiol production are highly related to one  
48 another, as are measures of progesterone production, however the two hormones also show some  
49 independence from one another, and measures of cycle length and gonadotropin concentrations  
50 show even greater independence, indicating minimal integration within cycles.

51 What is known already: The menstrual cycle is typically conceptualized as a cohesive unit, with  
52 hormone levels, follicular development, and ovulation all closely inter-related within a single  
53 cycle. Empirical support for this idea is limited, however, and to our knowledge, no analysis has  
54 examined the relationships among all of these components simultaneously.

55 Study design, size, duration: 206 healthy, cycling Norwegian women participated in a prospective  
56 cohort study (EBBA-I) over the duration of a single menstrual cycle. Of these, 192 contributed  
57 hormonal and cycle data used in the current analysis.

58 Participants/materials, setting, methods: Subjects provided daily saliva samples throughout the  
59 menstrual cycle from which estradiol and progesterone concentrations were measured. FSH and  
60 LH concentrations were measured in serum samples from three points in the same menstrual  
61 cycle and cycle length characteristics were calculated based on hormonal data and menstrual  
62 records. A factor analysis was conducted to examine the underlying relationships among 22  
63 variables derived from the hormonal data and menstrual cycle characteristics.

64 Main results and the role of chance: Six rotated factors emerged, explaining 80% of the variance  
65 in the data. Of these, factors representing estradiol and progesterone concentrations accounted for  
66 37% and 13% of the variance, respectively. There was some association between measures of

67 estradiol and progesterone production within cycles, however cycle length characteristics and  
68 gonadotropin concentrations showed little association with any measure of ovarian hormone  
69 concentrations.

70 Limitations, reasons for caution: Our summary measures of ovarian hormones may be imprecise  
71 in women with extremely long or short cycles, which could affect the patterns emerging in the  
72 factor analysis. Given that we only had data from one cycle on each woman, furthermore, we  
73 cannot how address cycle characteristics may covary within individual women across multiple  
74 cycles.

75 Wider implications of the findings: Our findings are generalizable to other healthy populations  
76 with typical cycles, however may not be applicable to cycles that are anovulatory, extreme in  
77 length, or otherwise atypical. The results support previous findings that measures of estradiol  
78 production are highly correlated across the cycle, as are measures of progesterone production.  
79 Estradiol and progesterone concentrations are associated with one another, furthermore. However  
80 factor analysis also revealed more complex underlying patterns in the menstrual cycle,  
81 highlighting the fact that gonadotropin concentrations and cycle length characteristics are  
82 virtually independent of ovarian hormones. These results suggest that despite integration of  
83 follicular and luteal ovarian steroid production across the cycle, cycle quality is a multi-faceted  
84 construct, rather than a single dimension.

85 Study funding/competing interest(s): The EBBA-I study was supported by a grant from the  
86 Norwegian Cancer Society (49 258, 05087); Foundation for the Norwegian Health and  
87 Rehabilitation Organizations (59010-2000/2001/2002); Aakre Foundation (5695–2000, 5754–  
88 2002), and Health Region East. The current analyses were completed under funding from the  
89 National Institutes of Health (K12 ES019852).

90

91 Keywords: menstrual cycle length, gonadotropin, estradiol, progesterone, ovarian function;

92

93 **Introduction**

94

95 The menstrual cycle is typically characterized as a single, cohesive unit in which hormone levels,  
96 follicular development, and ovulation are all closely inter-related. From this perspective, high  
97 quality cycles are not only ovulatory, but have high estradiol and progesterone concentrations,  
98 characteristic mid-cycle LH and FSH peaks, and are approximately 28 days in length. At the  
99 other end of the spectrum, low quality cycles are not only anovulatory, but may have low  
100 estradiol and progesterone concentrations, lack discernible LH and FSH peaks, and be atypical in  
101 length. In other words, the classical view of the menstrual cycle implies that the quality of a  
102 given cycle is consistent across multiple measures, including follicular development, ovarian  
103 steroid and gonadotropin concentrations, endometrial development, and cycle length  
104 characteristics. This concept of consistent quality across the cycle is often implicitly accepted,  
105 however few studies have directly examined this question. Certainly at the extreme end of the  
106 spectrum of impaired ovarian function, multiple aspects of hormone production and cycle  
107 characteristics can all be compromised, with possible cessation of menses and hormone cycling  
108 (Ellison, 1990). Within the range of typical, healthy cycling, however, the degree of cohesiveness  
109 or integration of cycle quality remains unclear. Empirically, if the quality of a cycle really is a  
110 single dimension, the various measurable components should show a high degree of covariance  
111 within cycles. The goal of the current analysis is to examine patterns of association among  
112 component parts of the menstrual cycle (estradiol concentrations, progesterone concentrations,  
113 gonadotropin concentrations, and cycle length variables) in order to better understand the normal  
114 menstrual cycle.

115

116 Theoretical support for close correlation of estradiol and progesterone production comes from the  
117 fact that both ovarian steroids derive from the same underlying structures. That is, the very cells

118 that produce estradiol in the follicular phase- the theca and granulosa cells of the preovulatory  
119 follicle- are those that go on to comprise the progesterone-producing cells of the corpus luteum  
120 after ovulation (Strauss and Williams, 2004). Based purely on the underlying cellular physiology,  
121 therefore, we might predict consistency of ovarian steroid production across the menstrual cycle  
122 (e.g. robust follicular estradiol production associated with robust luteal estradiol and progesterone  
123 production). On the other hand, estrogen and progesterone play different physiological roles in  
124 reproduction, and epidemiological evidence indicates that they can vary independently of one  
125 another (Lipson and Ellison, 1996, Nunez-De La Mora, et al., 2008, Nunez-de la Mora, et al.,  
126 2007, Venner, et al., 2006). For instance, one study measuring daily ovarian hormone profiles in  
127 premenopausal women found very low correlations between urinary estrogen and progesterone  
128 metabolite concentrations within a cycle ( $r=-0.003$  to  $0.13$ ) (Windham, et al., 2002). Thus,  
129 although a high degree of consistency between estradiol and progesterone indices might be  
130 expected, empirical support for that prediction is mixed.

131

132 Much as we might expect consistency of ovarian steroid hormone production within a cycle, so  
133 might we predict that ovarian steroid production is closely associated with production of pituitary  
134 gonadotropins. Ovarian steroid hormone production and release comes from coordination of  
135 ovarian theca and granulosa cell activity and is dependent upon gonadotropin input from the  
136 pituitary gland, with luteinizing hormone (LH) stimulating theca cell function, while follicle  
137 stimulating hormone (FSH) influences estradiol production by the granulosa cells (Strauss and  
138 Williams, 2004). Although some follicular development can proceed in the absence of FSH  
139 stimulation suggesting there is limited ovarian hormone activity independent of pituitary input  
140 (Oktay, et al., 1998), gonadotropin stimulation is essential for advancing further to the steroid-  
141 producing antral phase (Irving-Rodgers, et al., 2001). The complex feedback interactions between  
142 gonadotropins and ovarian steroids continue throughout mid-cycle, when rising follicular  
143 estradiol levels drive preovulatory surges in FSH and LH (Richards, et al., 2002). The apparent

144 interdependence of gonadotropin and ovarian steroid activity characteristic of normal ovarian  
145 function suggests that the two may be closely associated throughout the cycle, at least during  
146 certain periods. For instance, in one study of cycling women, there were weak correlations  
147 between estradiol and FSH early in the follicular phase, but higher (inverse) correlations in the  
148 mid-follicular phase (Robertson, et al., 2009) and other studies have found that estradiol has  
149 inhibitory effects on FSH secretion in the luteal phase (de Ziegler, et al., 1992, Lahlou, et al.,  
150 1999, Lasley, et al., 1975). In the luteal phase, moreover, both LH and FSH show weak to  
151 moderate negative correlations with progesterone concentrations, while LH and estradiol  
152 concentrations show a weak positive correlation (Robertson, et al., 2009). Thus there is evidence  
153 to suggest some coordination of pituitary gonadotropin and ovarian steroid production within the  
154 cycle, although the strength and direction of the relationship may vary at different points in the  
155 cycle.

156

157 That cycle length variables should be linked to hormone concentrations and follicular  
158 development is less obvious, but this prediction follows from the physiology nonetheless. The  
159 length of the follicular phase reflects the speed at which the antral follicle is recruited and  
160 develops, and thus by extension, follicular phase length should be related to gonadotropin and  
161 ovarian steroid concentrations as well (Cabral and de Medeiros, 2007, Harlow, et al., 2000).  
162 Experimental evidence in primates suggests that if the antral follicle is destroyed, the  
163 characteristic preovulatory gonadotropin surge is delayed, extending both the length of follicular  
164 phase and that of the total cycle (Goodman, et al., 1977). In humans, a limited body of work  
165 suggests associations between ovarian steroid concentrations and cycle length parameters,  
166 including total cycle length, follicular phase length, and luteal phase length, arguing further for  
167 consistency of cycle quality across multiple domains (Harlow, et al., 2000, Landgren, et al., 1980,  
168 Windham, et al., 2002). In particular, short follicular phases and short cycles may be associated  
169 with relatively high estrogen and progesterone concentrations, whereas longer follicular phases

170 may be characterized by lower average estrogen concentrations (Harlow, et al., 2000, Landgren,  
171 et al., 1980). Other studies have also observed positive correlations between progesterone levels  
172 and luteal phase length (Landgren, et al., 1980, Windham, et al., 2002).

173

174 To date, it has been difficult to study associations among different measures of ovarian function  
175 across the menstrual cycle because of the difficulty of obtaining repeated measures of hormonal  
176 variables across the entire cycle. Only a handful of studies have measured complete, daily  
177 estradiol and progesterone profiles over the course of one or more cycles (De Souza, et al., 1998,  
178 Liu, et al., 2004, Matthews, et al., 2006, Santoro, et al., 2004, Windham, et al., 2002). The  
179 convenience and non-invasiveness of saliva collection compared to blood or urine makes it an  
180 ideal medium for measuring daily ovarian steroid profiles. However the extremely low  
181 concentrations of estradiol in saliva made these analyses prohibitively difficult until relatively  
182 recently (O'Rourke and Ellison, 1993). In this analysis using data from healthy, cycling women  
183 participating in the Norwegian Energy Balance and Breast Cancer Aspects-I (EBBA-I) study, we  
184 adopt a factor analysis approach to examine whether the menstrual cycle truly is a cohesive unit.  
185 In particular, we focus on the relationships among four aspects of the menstrual cycle (estradiol  
186 concentrations, progesterone concentrations, gonadotropin concentrations, and measures of cycle  
187 length), looking at the strength of the associations between these components within cycles.

188

## 189 **Methods**

190

### 191 *Subject population, participants, and study design*

192 Women were recruited for the EBBA-I study, based in Tromsø, Norway, between 2000 and 2002.  
193 The study's goal was to examine the role of energetics and other lifestyle variables on known  
194 breast cancer risk factors in healthy, premenopausal women. To participate, women had to be age  
195 25-35 with regular menstrual cycles and could not have been pregnant, lactated, or used hormonal



196 contraception in the previous six months. Women with known histories of infertility,  
197 gynecological disorders, and chronic illnesses (such as type II diabetes) were excluded as well.  
198 In total, 206 women participated in EBBA-I, and the subject population, recruitment methods,  
199 and study design have been described elsewhere in detail (Furberg, et al., 2005). Subjects  
200 received 1000 Norwegian kroner (approximately \$160 US dollars at the time) to cover  
201 transportation and other expenses related to their participation.

202

### 203 *Ethical approval*

204 Participating women signed informed consent and the study was approved by the Regional  
205 Committee for Medical Research Ethics and the Norwegian Data Inspectorate as well as the  
206 human subjects review boards at all participating institutions.

207

### 208 *Salivary steroid assay*

209 As part of the study, subjects collected daily waking saliva samples over an entire menstrual  
210 cycle according to protocols developed by the Reproductive Ecology Laboratory at Harvard  
211 University (Lipson and Ellison, 1989). Free estradiol concentrations were assayed in samples  
212 from 20 cycle days (reverse cycle days -5 to -24), and progesterone concentrations were assayed  
213 for the last 14 days of each cycle (reverse cycle days -1 to -14). Levels of both hormones were  
214 measured using I-125-based radioimmunoassay (RIA) kits (Diagnostics Systems Laboratory,  
215 Webster, TX, USA) using methods reported elsewhere (Furberg, et al., 2005). The sensitivity of  
216 the estradiol assay was 4 pmol/L (1.1 pg/mL), the average intra-assay variability was 9%, and the  
217 interassay variability ranged from 23% to 13% for the low and high pools, respectively. The  
218 sensitivity of the progesterone assay was 13 pmol/L (4.1 pg/mL). Based on our assayed samples,  
219 the average intra-assay variability was 10%, and the inter-assay variability ranged from 19% to  
220 12% for the low and high pools, respectively.

221

222 Once estradiol assays had been completed, the daily concentrations across each cycle were  
223 examined in order to identify the day of the greatest mid-cycle drop in estradiol using methods  
224 described elsewhere (Lipson and Ellison, 1996). For each cycle, a mid-cycle estradiol “drop day”  
225 was first determined. The drop day was defined as the second of the two consecutive days in a  
226 mid-cycle window during which the greatest decrease in estradiol occurred. The mid-cycle  
227 window for identifying peak estradiol was days -18 to -12, thus the drop day was constrained to  
228 fall between days -17 to -11. This estradiol drop provides a good marker for the timing of  
229 ovulation, and the drop day was subsequently designated as day ‘0’. Thus days in the follicular  
230 phase have negative prefixes (e.g. day -1, day -2), whereas days in the luteal phase have positive  
231 prefixes (e.g. day +1, day +2). A drop day could not be assigned for 14 subjects. Eight of the 14  
232 had missing hormone data for at least one day during the interval between reverse cycle days -18  
233 to -12. The remaining six subjects had no discernable rise or drop in estradiol during the critical  
234 time window and their mid-cycle LH levels were low as well, suggesting that the cycles were  
235 anovulatory. Because determination of drop day is needed to calculate hormonal indices and  
236 separate cycles into follicular and luteal phases, these 14 women were excluded and only the 192  
237 women with aligned cycles were included in analyses.

238

### 239 *Creation of ovarian hormone indices*

240 From the daily estradiol and progesterone concentrations we were able to calculate a number of  
241 different indices of hormone levels, representing different components or periods of ovarian  
242 function. Each index was calculated as the mean hormone concentration across samples collected  
243 during a particular period of the cycle relative to ovulation (day 0). Seven estradiol indices were  
244 calculated for each cycle: *total estradiol* (mean estradiol for all cycle days measured) reflects  
245 average estradiol exposure across the cycle; *follicular estradiol* (mean estradiol, days -10 to -1)  
246 reflects average estradiol prior to ovulation; *mid-follicular estradiol* (mean estradiol, days -10 to -  
247 6) reflects estradiol production around the time of the emergence of the dominant follicle; *late*

248 *follicular estradiol* (mean estradiol, days -5 to -1) reflects the secretory activity of the dominant  
249 follicle prior to ovulation; *maximum follicular estradiol* (highest estradiol concentration  
250 measured between days -10 to -1), *maximum estradiol* (highest estradiol at any point in the  
251 cycle), and *magnitude of the midcycle estradiol drop* (maximum estradiol minus estradiol on day  
252 0) reflect midcycle estradiol secretion as well as the decrease in circulating estradiol  
253 accompanying ovulation of the dominant follicle. If follicular phase length was shorter than 10  
254 days, follicular estradiol and mid-follicular estradiol calculations were adjusted accordingly (e.g.  
255 if the follicular phase was only 9 days, was calculated as the mean of days -9 through -1, rather  
256 than -10 through -1). Similarly, if data were missing (for instance, due to estradiol concentrations  
257 below the sensitivity limit at the beginning of the cycle), indices were calculated as the mean  
258 across the days with measurable concentrations in that interval.

259  
260 Six indices of progesterone concentrations were calculated as well. *Total progesterone* (mean  
261 progesterone, days 0 to +14) reflects average progesterone exposure during the luteal phase;  
262 *early-mid luteal progesterone* (mean progesterone, days 0 to +9) represents the average  
263 circulating progesterone concentrations during the beginning and middle of the luteal phase; *mid-*  
264 *luteal progesterone* (mean progesterone, days +5 to +9) reflects the level of progesterone  
265 secretion at the peak of the luteal phase; *very early luteal progesterone* (mean progesterone, days  
266 0 to +2) and *early luteal progesterone* (mean progesterone, days +3 to +5) together reflect the  
267 early luteal progesterone rise, before any possible effects of human chorionic gonadotropin (hCG)  
268 from a potential conceptus; and *late luteal progesterone* (mean progesterone, days +10 to +14)  
269 reflects post-peak secretion of progesterone during the regression of the corpus luteum prior to  
270 menstruation. If luteal phase length was shorter than 14 days, total progesterone and late luteal  
271 progesterone calculations were adjusted accordingly (e.g. if the luteal phase was 12 days, total  
272 progesterone was calculated as the mean of days 0 through +12, rather than 0 through +14).  
273 When progesterone values were missing for individual days, the hormone indices were calculated

274 as the means of those days with data. Summary statistics for the hormonal variables are provided  
275 in Table 2.

276

#### 277 *Calculation of menstrual cycle phase lengths*

278 Three cycle length variables were measured using the hormone data and self-reported dates of  
279 menses. *Overall cycle length* was the number of days from menstrual onset to menstrual onset, as  
280 determined by self-reported menses. *Follicular phase length* was the number of days from  
281 menstrual onset to the mid-cycle estradiol drop day. Finally, *luteal phase length* was the number  
282 of days from the day after the mid-cycle estradiol drop day to onset of subsequent self-reported  
283 menses.

284

#### 285 *Serum sample collection and gonadotropin assay*

286 At three points in the cycle, fasting serum samples were taken by trained nurses at the University  
287 Hospital of Northern Norway, Tromsø. These collections were done between days 1-2, 7-12, and  
288 21, reflecting the early follicular, pre-ovulatory, and luteal phases of the cycle. Luteinizing  
289 hormone (LH) and follicular stimulating hormone (FSH) were measured in serum samples from  
290 all three time points using Techicon Immuno1 immunometric assays (Bayer Corp, Tarrytown,  
291 NY). Both assays were standardized against the WHO 2nd International Standard (for FSH: IRP  
292 78/549 and for LH: IRP 68/40). The sensitivity of the FSH assay was 0.1 IU/L and the coefficient  
293 of variation was less than 7 percent. For LH, the assay sensitivity was 0.3 IU/L and the  
294 coefficient of variation was 5-10 percent.

295

#### 296 *Statistical analyses*

297 All statistical analyses were carried out in SAS Enterprise 4.3 (SAS Corporation, Cary, NC).  
298 Because hormone values typically follow non-normal distributions, all hormone indices were first  
299 log transformed to normalize variances. We first examined bivariate correlations between the

300 ovarian hormone indices in our analysis. We then conducted a factor analysis by principal  
301 components extraction, with and without orthogonal varimax rotation of axes on the correlation  
302 matrix of the study variables. The goal of factor analysis is to condense a large number of  
303 correlated variables into a smaller number of factors and in doing so, reveal underlying  
304 relationships among the variables. Orthogonal varimax rotation then rotates these factors so that  
305 they are uncorrelated with one another, creating factors for which one or more variables have  
306 high loadings, while loadings for the other variables are close to zero (Manly, 2005). Each factor  
307 has an eigenvalue, which indicates the amount of variance in all of the variables that is accounted  
308 for by that factor, and following the conventionally used Kaiser criterion, only factors with  
309 eigenvalues greater than 1 (i.e. explaining more than 1 percent of the total variance) are retained  
310 in the analysis (Kaiser, 1958). Thus factors with large eigenvalues explain a large amount of  
311 variance in the overall data, whereas factors with small eigenvalues explain little of the variance.  
312 A Scree plot (which helps to visually discriminate between those factors explaining a large  
313 fraction of the variance and those which are relatively unimportant) was made to confirm the  
314 number of factors that should be included in the analysis. For each factor with an eigenvalue  
315 greater than 1, we examined the loading of each menstrual cycle variable, which is similar to a  
316 standardized regression coefficient when the factor is regressed on the variables (DeCoster,  
317 1998). Loadings of  $\geq 0.7$  were considered strong loadings, while those  $< 0.7$ , but  $\geq 0.35$  were  
318 considered moderate loadings. Loadings  $< 0.35$  were considered weak to negligible.

319

320 One of the useful aspects of principal component extraction is the collapsing of highly correlated  
321 variables into a smaller number of axes representing linear functions of those correlated variables.  
322 Here, for instance, although high correlations might be expected among the different indices of  
323 each steroid (particularly those that overlap), it is not necessarily the case that seemingly related  
324 indices would all cluster on the same rotated axes resulting from factor analysis. Luteal and  
325 follicular estradiol secretion, for example, might be governed by different patterns of

326 gonadotropin secretion and hence manifest significant independence. Similarly mid-follicular  
327 estradiol might reflect the combined secretory activity of a recruited cohort of follicles under FSH  
328 stimulation, whereas late follicular and maximum follicular estradiol presumably reflect secretion  
329 by the dominant follicle alone. The degree to which these aspects of estradiol production are  
330 independent will affect the degree to which they individually correlate with average estradiol  
331 levels over the entire follicular phase or the entire cycle as well. Thus the current analyses allow  
332 us to examine the relationships among the specified variables without making any *a priori*  
333 assumptions about the independence (or multicollinearity) of different indices of ovarian steroid  
334 levels and other cycle characteristics. Instead, factor analysis allows us to identify those clusters  
335 of variables that are highly redundant and thus reduce the number of indices studied.

336

### 337 **Results**

338

339 General characteristics of the study subjects are provided in Table 1. The study population was  
340 predominantly Caucasian and highly educated with a mean age of 30 years. 61% of subjects were  
341 married and half had at least one child. The average cycle length was 28 days (range: 20-47), of  
342 which 15 were spent in the follicular phase and 13 in the luteal phase. Bivariate analyses indicate  
343 moderate to strong positive correlations between the estradiol and progesterone indices and are  
344 presented in Table 2. Most of the estradiol indices have correlation coefficients with each other  
345 in the range 0.7 to 0.95. The exception is the magnitude of the midcycle estradiol drop, which  
346 correlates very weakly, and typically negatively, with the other estradiol variables. Similarly, the  
347 progesterone indices have correlation coefficients with each other in the range of 0.57 to 0.97.  
348 Except for magnitude of the estradiol drop, the correlations between the estradiol and  
349 progesterone indices are moderate, ranging from 0.38 to 0.60.

350

351 The unrotated factor matrix (not shown) generated six factors with eigenvalues greater than 1.  
352 Typically, the first unrotated factor represents the single vector that captures the greatest amount  
353 of the multivariate variance and in this case, all of the estradiol and progesterone measures (aside  
354 from the magnitude of the estradiol drop) had loadings of 0.70 or greater on Factor 1. Of the  
355 remaining variables, seven had loadings between 0.05 and 0.16, with the remaining three having  
356 loadings less than 0.05. Factor 1 of the unrotated matrix accounted for only 38% of the total  
357 multivariate variance in the sample, however, indicating that the majority of the multivariate  
358 variance could not be captured by a single axis.

359

360 Subsequent orthogonal varimax rotation of the axes obtained from the factor analysis maximized  
361 the separation of the factor loadings of the original variables onto different axes and generated six  
362 rotated factors with eigenvalues greater than 1, which together explained 80 percent of the  
363 variation in the data. Factor loadings for the six rotated factors are presented in Table 3. The  
364 varimax rotation largely succeeded in separating the original variables onto different axes, each of  
365 which was orthogonal to, or independent of, the others. All variables loaded on at least one  
366 factor, but no variable had a strong loading ( $\geq 0.7$ ) on more than one factor. Two variables, mid-  
367 cycle LH and mid-cycle FSH, showed split moderate loadings on more than one factor. Mid-  
368 cycle LH loaded strongly on Factor 5 and moderately (and negatively) on Factor 3, while mid-  
369 cycle FSH showed a moderate, negative loading on Factor 3, and moderate, positive loadings on  
370 Factors 4 and 5. Only two original variables, mid-cycle FSH and magnitude of the mid-cycle  
371 estradiol drop, did not have a strong loading on any of the six rotated factors. Mid-cycle FSH  
372 instead had moderate loadings on three factors, while the magnitude of the mid-cycle estradiol  
373 drop had a moderate loading on one factor.

374

375 The first rotated factor explained 37% of the variance and included all of the measures of  
376 estradiol except for the magnitude of the mid-cycle estradiol drop. The second rotated factor

377 included the six progesterone indices and explained 13% of the variance. The third rotated factor  
378 accounted for 11% of the variance and included cycle length and follicular phase length with  
379 minor loadings on mid-cycle gonadotropin concentrations. The fourth rotated factor explained  
380 9% of the variance and included luteal gonadotropin concentrations, with a minor loading on  
381 mid-cycle FSH concentrations and the magnitude of the estradiol drop. The fifth rotated factor,  
382 explaining 5% of the variance, had major loadings on early follicular and mid-cycle LH  
383 concentrations and minor loadings on early follicular and mid-cycle FSH loadings. Finally, only  
384 luteal phase length was included in the sixth rotated factor, which accounted for 5% of the  
385 variance in the data set. Sensitivity analyses (not shown) using only subjects with complete daily  
386 hormone data did not change the basic relationships among variables and factors.

387

## 388 **Discussion**

389

390 The purpose of this analysis is to examine the extent to which the menstrual cycle is a cohesive  
391 unit in healthy, reproductive-age women, as measured by the strength of the relationships among  
392 hormonal measurements and cycle characteristics. Or, phrased as a question, to what extent is any  
393 one measure of menstrual function predictive of or independent of others within the same cycle?  
394 Of particular interest is the extent to which there is coordination of ovarian steroid production  
395 across the follicular and luteal phases of the cycle. In our study population, the relationship  
396 between follicular phase estradiol and luteal phase progesterone is significantly positive, as  
397 reflected in the bivariate correlations. These correlations are much higher than reported in at least  
398 one other study in cycling women, in which correlations between urinary estradiol and  
399 progesterone metabolite concentrations were 0.13 or lower (Windham, et al., 2002). Because  
400 urinary assays measure conjugated metabolite concentrations and are thus one or more steps  
401 removed from circulating free hormone concentrations, such assays may introduce additional  
402 noise related to inter-individual metabolic variation (Gann, et al., 2001). For that reason, the



403 stronger correlations found in the current study based on free (bioactive) salivary steroid  
404 concentrations may be a more accurate reflection of the true relationship between estradiol and  
405 progesterone concentrations in healthy, cycling women.

406

407 In the current study, the positive association between follicular and luteal steroid profiles is  
408 further illustrated by sorting the study subjects into quartiles on the basis of the indices of one  
409 steroid and comparing the full daily profiles of the other. Sorting the subjects into quartiles by  
410 mean follicular estradiol concentrations shows that women with high mean follicular estradiol  
411 concentrations also tend to have high progesterone concentrations throughout the luteal phase  
412 (Figure 1). Similarly, when subjects are sorted by mean luteal progesterone concentrations, those  
413 with the highest quartile of luteal progesterone concentrations tend to have high follicular  
414 estradiol concentrations as well (Figure 2). In both cases, the quartiles are clearly distinct from  
415 one another. Thus crude analyses suggest that, across women, within a cycle, levels of one of  
416 these hormones are indicative of levels of the other.

417

418 The subsequent factor analysis allowed simultaneous examination of the relationships between  
419 the ovarian steroid concentrations and other measures of cycle quality to identify more complex  
420 underlying patterns. The factors obtained after varimax rotation represent the “sorting” of  
421 variables into groups that are highly correlated among the group while being orthogonal, or  
422 independent, of the groups represented by other factors. Factor 1 has very strong loadings (0.85 or  
423 greater) for all the estradiol indices except the magnitude of the estradiol drop. It reflects the high  
424 consistency of estradiol production across the ovarian cycle and supports previous work finding  
425 high correlations between estradiol measures at multiple points across the cycle (Windham, et al.,  
426 2002). The progesterone indices load weakly on this factor (0.20 to 0.30), with loadings being  
427 highest for early luteal progesterone measures and lower for indices capturing the later part of the  
428 luteal phase. This suggests that estradiol and progesterone production cannot be fully

429 disentangled, particularly in the early luteal phase. Factor 2 has very high loadings (0.73 or  
430 greater) for all the progesterone indices, suggesting that progesterone production is highly  
431 consistent across the luteal phase. In Factor 2 there are weak loadings (0.2 to 0.34) for most of the  
432 estradiol indices, again indicating that there is some aspect of the relationship between  
433 progesterone and estradiol production that cannot be disarticulated, as suggested in the crude  
434 analyses.

435

436 Nevertheless, the degree to which indices of the two ovarian steroids separate onto different axes  
437 in the factor analysis reflects the degree to which they are actually independent of each other. It is  
438 noteworthy, that no other variables have loadings on the first two rotated factors, which we  
439 therefore regard as the estradiol and progesterone factors, respectively. In particular, the loadings  
440 for both the gonadotropin variables and the cycle length measures are extremely low. This  
441 suggests that a woman's circulating estradiol and progesterone concentrations are not a clear  
442 function of her circulating gonadotropin concentrations, nor are they closely related to her cycle  
443 length. Rather, other factors including gonadotropin receptor densities or sub-types, co-  
444 gonadotropins such as insulin and IGF-1, or other unknown genetic, developmental, or  
445 constitutional components may explain inter-individual variance in ovarian steroid  
446 concentrations. It remains possible that differences in gonadotropin concentrations may account  
447 for more of the documented within-individual variance in ovarian steroid concentrations (between  
448 multiple cycles in the same woman, for instance) (Lipson and Ellison, 1996, Venners, et al.,  
449 2006).

450

451 Factor 3 has very high loadings (0.88 or greater) for total cycle length and follicular phase length,  
452 which confirms the close association between follicular phase length and overall cycle length that  
453 has been noted elsewhere (Fehring, et al., 2006, Waller, et al., 1998). The moderate negative  
454 loadings of the mid-cycle concentrations of LH and FSH on this factor are more surprising,

455 suggesting that factors associated with slow follicular growth (resulting in a longer follicular  
456 phase and longer total cycle length) may later result in poor steroid response in the luteal phase.  
457 Because this factor is independent of steroid concentrations themselves (Factors 1 & 2), even in  
458 the luteal phase, it may indicate that higher gonadotropin levels are required to stimulate a given  
459 amount of steroid production in cycles with longer follicular phases than in those with shorter  
460 follicular phases. This may again be consistent with variation in the ovarian responsiveness to  
461 gonadotropin stimulation rather than the level of that stimulation itself, an effect that might be  
462 moderated at the receptor level. Further study is needed to understand these unexpected  
463 relationships.

464

465 Factor 4 has strong loadings (0.80 or greater) for luteal FSH and LH concentrations. It also has  
466 moderate loadings for mid-cycle FSH (0.49) and the magnitude of the mid-cycle estradiol drop  
467 (0.41). It is noteworthy that the magnitude of the mid-cycle estradiol drop only clusters with luteal  
468 gonadotropins (albeit moderately) and not with any of the ovarian steroid measures. In fact,  
469 magnitude of the mid-cycle estradiol drop is the only steroid index that correlates significantly  
470 with levels of gonadotropin stimulation, although it is somewhat surprising that it clusters with  
471 luteal, rather than mid-cycle gonadotropin concentrations. Baseline gonadotropin concentrations  
472 tend to be very low across the entire luteal phase and pulsatile release of gonadotropins occurs at  
473 low frequency (Hall, 2004, Johnson and Everitt, 2000), so it is unclear why they should be  
474 associated with the magnitude of the estradiol drop. Additional research is needed to confirm and  
475 better understand this unexpected observation.

476

477 Factor 5 has high loadings (greater than 0.70) for early follicular and mid-cycle LH, with  
478 moderate loadings (0.5-0.7) for early follicular and mid-cycle FSH. This indicates that  
479 gonadotropin concentrations in the first half of the cycle are closely associated even though the  
480 two have distinct functional differences, with FSH stimulating further development of the antral

481 follicle while LH promotes ovarian steroid production and eventually, ovulation (Hall, 2004,  
482 Strauss and Williams, 2004). Nevertheless, given that both are produced and secreted by a  
483 common source (the pituitary gland) and that both are responsive to fluctuating ovarian steroid  
484 concentrations (through negative feedback), it is not surprising that FSH and LH concentrations  
485 would load on the same factor. More surprising, perhaps, is how weak the ovarian steroid  
486 loadings are on this factor, which may indicate that across women, there is little relationship  
487 between early follicular and mid-cycle gonadotropins and ovarian steroid concentrations. Once  
488 again, this suggests that it may be sensitivity to gonadotropin stimulation (for instance through  
489 receptor densities or the effect of co-gonadotropins), and not absolute gonadotropin  
490 concentrations that are most important for regulating ovarian steroid production.

491

492 Finally, only luteal phase length loads on Factor 6 (0.97), indicating that it is virtually  
493 independent of the other hormone and cycle characteristics considered in this analysis. It is not  
494 surprising that luteal phase length did not cluster with the other cycle length variables given that  
495 the literature suggests that while total cycle length and follicular phase length are tightly  
496 correlated, luteal phase length tends to be less variable and show only moderate correlations with  
497 both (Fehring, et al., 2006, Waller, et al., 1998). In fact, one study found that only three percent  
498 of the variance in total cycle length was attributable to variation in luteal phase length, whereas  
499 follicular phase variation explained over 84 percent (Waller, et al., 1998). At least one study has  
500 identified differences in urinary ovarian steroid concentrations in relation to luteal phase length,  
501 however those differences were in comparisons of cycles with short ( $\leq 10$  days), average (11-14  
502 days), and long ( $\geq 15$  days) luteal phases and did not consider luteal phase lengths continuously  
503 within the normal range (Windham, et al., 2002). In general, little is known about predictors or  
504 determinants of luteal phase length and additional research is needed to understand the existing  
505 variation and how it is related to other cycle indicators of ovarian function.

506

507 Overall, the results of this factor analysis suggest that although there is some consistency of  
508 menstrual function across domains, the particular cycle measures considered here also show  
509 considerable independence from one another across women. Perhaps of greatest interest are the  
510 associations between estradiol and progesterone indices, which clustered onto two distinct  
511 factors, but also showed minor loadings on each other's primary factors, suggesting some inter-  
512 dependence between the two. This finding is interesting in light of previous work suggesting that  
513 follicular estradiol concentrations are higher in conception cycles than non-conception cycles  
514 (Lipson and Ellison, 1996). One explanation is that high estradiol concentrations better stimulate  
515 the developing oocyte and prime the endometrium for proliferation, thus increasing the odds of a  
516 successful conception. Our results suggest a second explanation should be considered as well,  
517 namely that there may also be correlated luteal phase effects, including endometrial secretions  
518 and support for implantation that is necessary for successful conception. The associations  
519 between estradiol measures (which are primarily follicular) and progesterone measures (which  
520 are luteal) is clinically important, moreover, in that it further supports the idea that luteal phase  
521 defects are actually product of problems with follicular development earlier in the cycle  
522 (DiZerega and Hodgen, 1981).

523

524 At the same time, estradiol and progesterone measures also showed a degree of independence  
525 from one another, and the fact that ovarian steroid concentrations were not associated with  
526 variation in gonadotropin concentrations or in cycle and phase lengths, moreover, suggests that it  
527 may be mediated by tissue sensitivity, perhaps reflecting differences in receptor expression or  
528 variation, or other physiological, genetic, developmental, or constitutional factors. Such a  
529 mechanism would be consistent with findings of a study of adult Bangladeshi migrants to the UK,  
530 that indicated that progesterone, but not estradiol, was related to individual developmental history  
531 (Nunez-De La Mora, et al., 2008, Nunez-de la Mora, et al., 2007). Indeed, at least one study  
532 found that progesterone levels tend to be predictable within individuals over intervals of as much

533 as one year, whereas estradiol levels may vary dramatically within individuals over the same time  
534 period (Chatterton, et al., 2005). The dissociation of estradiol and progesterone profiles observed  
535 in such studies suggests that developmental history may exert long-lasting influence on some  
536 aspects of ovarian steroid production, whereas other aspects are more responsive to acute cues in  
537 the immediate environment.

538

539 There are some limitations to the interpretation of results from this study. First, the current study  
540 assessed only inter-individual effects, finding, for instance, that women who have high estradiol  
541 levels tend to have high progesterone levels and vice versa. Because hormone levels were only  
542 measured for the duration of a single cycle in this study, we are unable to examine whether the  
543 same trend holds between cycles within individual women. Additional research following women  
544 longitudinally over time is needed to determine whether, within a given woman, high estradiol  
545 cycles are likely to also feature high progesterone levels, while low estradiol cycles tend to have  
546 low progesterone levels. Similarly, our results do not address whether other cycle characteristics  
547 tend to covary within individual women across multiple cycles.

548

549 Because we measured estradiol concentrations only in samples collected on reverse cycle days -5  
550 to -24 (i.e. from 5 to 24 days before the start of the next menstrual bleeding), our estradiol indices  
551 may be inaccurate for any women with extremely long cycles. Although the recruitment criteria  
552 generally excluded women with atypical cycles, in practice, approximately 5 percent of subjects  
553 had cycles longer than 35 days. In a 35 day cycle, for instance, by assaying estradiol  
554 concentrations only in days -5 to -24 of the cycle, our calculated estradiol indices are artificially  
555 truncated, omitting concentrations in the early follicular phase. By contrast, in women with  
556 shorter cycles, nearly the entire follicular phase would be captured in our estradiol indices.

557 Similarly, given that progesterone concentrations were only assayed in sample from reverse cycle  
558 days -1 to -14 (i.e. from 1 to 14 days before the start of the next menstrual bleeding), in women

559 with extremely long luteal phases, the progesterone indices might not capture the earliest days of  
560 the luteal phase. For several reasons, however, we believe that this potential error is unlikely to  
561 affect our results. First, we conducted a sensitivity analysis (not shown) restricting the analyses  
562 to subjects with cycle lengths ranging from 24-34 days and found that although there were slight  
563 differences in the exact factor loadings, the patterns and relationships that emerged were  
564 unchanged from those found using the whole cohort. Second, the fact that ovarian hormones and  
565 cycle phase lengths load on different factors in our analysis suggests the two are largely  
566 independent of one another. If there were significant confounding of these variables, there would  
567 have been strong loadings of ovarian hormone and cycle length characteristics on the same  
568 factors, which there was not. Ultimately, if there were bias due to improper calculation of  
569 hormone indices in long cycles, it would be for cycles with longer follicular phases to have higher  
570 average estradiol levels (since it would be the early follicular levels, which are typically low, that  
571 were omitted from the calculated indices), and we do not see any evidence of that. Any bias in  
572 progesterone levels due to cycle length would be similar, but there is strong evidence from many  
573 studies, including these data, that variation in luteal phase length is minimal (Matsumoto, et al.,  
574 1962, Vollman, 1977). Thus we suggest that any bias in this regard is negligible.

575

576 Another limitation is our subject population, which was specifically recruited to be ages 25-35  
577 and self-identifying as having regular cycles. Our population's cycle length and cycle phase  
578 lengths were typical of healthy women in this age range, however we cannot necessarily  
579 extrapolate our findings to address this question in other groups of women (Chiazze, et al., 1968,  
580 Treloar, et al., 1967, Vollman, 1977). In particular, women with less typical cycles (who would  
581 have been excluded from participation in the current study) might show different patterns of cycle  
582 hormones and characteristics, as might the 14 subjects whose hormonal profiles did not allow us  
583 to readily identify an estradiol drop day (and hence were excluded from analysis). Whether these  
584 results also apply to younger and older women (whose cycles may tend to be more erratic and

585 have lower hormone levels) remains unknown (Chiazze, et al., 1968, Lipson and Ellison, 1992,  
586 Treloar, et al., 1967). Further research is also needed to determine whether these patterns hold  
587 true in non-Western populations in which the level of ovarian function (as evidenced by estradiol  
588 and progesterone concentrations) is typically lower (Ellison, et al., 1993). Given the results of  
589 migrant studies (Nunez-De La Mora, et al., 2008, Nunez-de la Mora, et al., 2007), it may be of  
590 particular interest to examine women whose current environment differs radically from the  
591 environment in which they were born and raised. Perhaps under such conditions, there will be  
592 even weaker relationships across domains, with different cycle components reflecting  
593 developmental and current conditions.

594

595 Finally, our findings on the relative independence of gonadotropin concentrations from other  
596 measures of cycle quality should be interpreted with caution. As discussed, one possibility is that  
597 although serum gonadotropin concentrations may not be directly associated with ovarian steroid  
598 concentrations or cycle length characteristics, other indicators of gonadotropin activity (such as  
599 ovarian receptor densities) may be. It is also possible, however, that because gonadotropins are  
600 released in approximately hourly pulses (Kazer, et al., 1987, Moret, et al., 2009), our  
601 measurement techniques (based on single serum samples at three points in the cycle) may have  
602 been too imprecise to capture circulating concentrations and have resulted in additional “noise” in  
603 our data. Gonadotropin concentrations would be better quantified by repeated blood sampling at  
604 short intervals (approximately five minutes) during an extended time period followed by pulse  
605 detection analysis (Moret, et al., 2009). Even with that improved methodology, however, we  
606 would not be able to address whether the serum gonadotropin concentrations reflected the  
607 concentrations in the follicle, which are ultimately of greatest relevance and interest.

608

609 In conclusion, this study is the first to directly address the extent to which multiple components of  
610 the menstrual cycle and ovarian function are inter-related in healthy, cycling, Western women.



611 We have found that there is a significant degree of coordination of ovarian steroid production  
612 across the cycle, however estradiol and progesterone production also show considerable  
613 independence from one another. We have determined, furthermore, that across women,  
614 circulating gonadotropin concentrations and cycle length characteristics are almost entirely  
615 unrelated to ovarian steroid concentrations, suggesting that these aspects of cycle quality are  
616 independent of one another. Contrary to the textbook depiction of the menstrual cycle, cycle  
617 quality is not uniform across measures. Even in healthy, cycling women, different components of  
618 the cycle (ovarian steroids, gonadotropins, and cycle phase lengths) do not necessarily covary in a  
619 straight-forward, predictable manner. Future research may look at not only how these measures  
620 of ovarian function are related to (or independent of) one another within women, but also how  
621 additional aspects of ovarian function, such as follicular development, follicular gonadotropin  
622 levels, or endometrial proliferation fit into this complex system.

623

**624 Authors' Roles:**

625

626 E.B. analyzed and interpreted the data and drafted the manuscript. P.E. directed hormone

627 analyses in the study and helped with data interpretations and manuscript drafting. S.L.

628 conducted the hormone analyses in the study and edited the manuscript for intellectual content.

629 A.F. helped to design the study, implement it, and critically reviewed the manuscript. I.T.

630 designed the study, directed implementation and data collection, and critically reviewed the

631 manuscript.

632

**633 Acknowledgements:**

634

635 We thank the Norwegian EBBA-I study subjects, as well as our research staff, Gunn Knudsen,

636 Anna Kirsti Jensen, and Sissel Andersen. In addition, we thank Lauren Parlett for her assistance

637 in preparing graphics.

638

**639 Funding:**

640 The EBBA-I study was supported by a grant from the Norwegian Cancer Society (49 258,  
641 05087); Foundation for the Norwegian Health and Rehabilitation Organizations (59010-  
642 2000/2001/2002); Aakre Foundation (5695–2000, 5754–2002), and Health Region East. The  
643 current analyses were completed under funding from the National Institutes of Health (K12  
644 ES019852). The content is solely the responsibility of the authors and does not necessarily  
645 represent the official views of the NIH.

646

647 **Conflicts of interest:**

648

649 The authors have no conflicts of interest to declare.

650

651 References:

652

653 Cabral ZA and de Medeiros SF. Follicular growth pattern in normal-cycling Brazilian  
654 adolescents. *Fertil Steril* 2007; 88:1625-1631.

655

656 Chatterton RT, Jr., Mateo ET, Hou N, Rademaker AW, Acharya S, Jordan VC and  
657 Morrow M. Characteristics of salivary profiles of oestradiol and progesterone in  
658 premenopausal women. *J Endocrinol* 2005; 186:77-84.

659

660 Chiazze L, Jr., Brayer FT, Macisco JJ, Jr., Parker MP and Duffy BJ. The length and  
661 variability of the human menstrual cycle. *JAMA* 1968; 203:377-380.

662

663 De Souza MJ, Miller BE, Loucks AB, Luciano AA, Pescatello LS, Campbell CG and  
664 Lasley BL. High frequency of luteal phase deficiency and anovulation in recreational  
665 women runners: blunted elevation in follicle-stimulating hormone observed during luteal-  
666 follicular transition. *J Clin Endocrinol Metab* 1998; 83:4220-4232.

667

668 de Ziegler D, Bergeron C, Cornel C, Medalie DA, Massai MR, Milgrom E, Frydman R  
669 and Bouchard P. Effects of luteal estradiol on the secretory transformation of human  
670 endometrium and plasma gonadotropins. *J Clin Endocrinol Metab* 1992; 74:322-331.

671

672 DeCoster J. Overview of Factor Analysis. 1998, <http://www.stat-help.com/notes.html>.

673

674 DiZerega GS and Hodgen GD. Luteal phase dysfunction infertility: a sequel to aberrant  
675 folliculogenesis. *Fertil Steril* 1981; 35:489-499.

676

677 Ellison PT. Human ovarian function and reproductive ecology: new hypotheses.  
678 *American Anthropologist* 1990; 92:933-952.

679

680 Ellison PT, Panter-Brick C, Lipson SF and O'Rourke MT. The ecological context of  
681 human ovarian function. *Hum Reprod* 1993; 8:2248-2258.

682

683 Fehring RJ, Schneider M and Raviele K. Variability in the phases of the menstrual cycle.  
684 *J Obstet Gynecol Neonatal Nurs* 2006; 35:376-384.

685

686 Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF, Ellison PT and  
687 Thune I. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of  
688 breast cancer risk. The Norwegian EBBA Study. *Cancer Epidemiol Biomarkers Prev*  
689 2005; 14:33-40.

690

691 Gann PH, Giovanazzi S, Van Horn L, Branning A and Chatterton RT, Jr. Saliva as a  
692 medium for investigating intra- and interindividual differences in sex hormone levels in  
693 premenopausal women. *Cancer Epidemiol Biomarkers Prev* 2001; 10:59-64.

694

- 695 Goodman AL, Nixon WE, Johnson DK and Hodgen GD. Regulation of folliculogenesis  
696 in the cycling rhesus monkey: selection of the dominant follicle. *Endocrinology* 1977;  
697 100:155-161.  
698
- 699 Hall JE. Neuroendocrine control of the menstrual cycle. In Strauss JF and Barbieri RL  
700 (eds) Yen and Jaffe's Reproductive Endocrinology. 2004. Elsevier Saunders,  
701 Philadelphia, PA, pp. 195-211.  
702
- 703 Harlow SD, Baird DD, Weinberg CR and Wilcox AJ. Urinary oestrogen patterns in long  
704 follicular phases. *Hum Reprod* 2000; 15:11-16.  
705
- 706 Irving-Rodgers HF, van Wezel IL, Mussard ML, Kinder JE and Rodgers RJ. Atresia  
707 revisited: two basic patterns of atresia of bovine antral follicles. *Reproduction* 2001;  
708 122:761-775.  
709
- 710 Johnson MH and Everitt BJ. Essential Reproduction. 5th edition edn, 2000. Blackwell  
711 Science, Oxford, U.K.  
712
- 713 Kaiser HF. The varimax criterion for analytic rotation in factor analysis. *Psychometrika*  
714 1958; 23:187-200.  
715
- 716 Kazer RR, Kessel B and Yen SS. Circulating luteinizing hormone pulse frequency in  
717 women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1987; 65:233-236.  
718
- 719 Lahlou N, Chabbert-Buffet N, Christin-Maitre S, Le Nestour E, Roger M and Bouchard  
720 P. Main inhibitor of follicle stimulating hormone in the luteal-follicular transition: inhibin  
721 A, oestradiol, or inhibin B? *Hum Reprod* 1999; 14:1190-1193.  
722
- 723 Landgren BM, Uden AL and Diczfalusy E. Hormonal profile of the cycle in 68  
724 normally menstruating women. *Acta Endocrinol (Copenh)* 1980; 94:89-98.  
725
- 726 Lasley BL, Wang CF and Yen SS. The effects of estrogen and progesterone on the  
727 functional capacity of the gonadotrophs. *J Clin Endocrinol Metab* 1975; 41:820-826.  
728
- 729 Lipson SF and Ellison PT. Development of protocols for the application of salivary  
730 steroid analyses to field conditions. *American Journal of Human Biology* 1989:249-255.  
731
- 732 Lipson SF and Ellison PT. Normative study of age variation in salivary progesterone  
733 profiles. *J Biosoc Sci* 1992; 24:233-244.  
734
- 735 Lipson SF and Ellison PT. Comparison of salivary steroid profiles in naturally occurring  
736 conception and non-conception cycles. *Hum Reprod* 1996; 11:2090-2096.  
737
- 738 Liu Y, Gold EB, Lasley BL and Johnson WO. Factors affecting menstrual cycle  
739 characteristics. *Am J Epidemiol* 2004; 160:131-140.

- 740 Manly BFJ. *Multivariate Statistical Methods: A Primer*. 3rd edn, 2005. Chapman &  
741 Hall/CRC, Boca Raton, FL.
- 742
- 743 Matsumoto S, Nogami Y and Ohkuri S. Statistical studies on menstruation: a criticism on  
744 the definition of normal menstruation. *Gunma J Med Sci* 1962; 11:294-318.
- 745
- 746 Matthews KA, Santoro N, Lasley B, Chang Y, Crawford S, Pasternak RC, Sutton-Tyrrell  
747 K and Sowers M. Relation of cardiovascular risk factors in women approaching  
748 menopause to menstrual cycle characteristics and reproductive hormones in the follicular  
749 and luteal phases. *J Clin Endocrinol Metab* 2006; 91:1789-1795.
- 750
- 751 Moret M, Stettler R, Rodieux F, Gaillard RC, Waeber G, Wirthner D, Giusti V, Tappy L  
752 and Pralong FP. Insulin modulation of luteinizing hormone secretion in normal female  
753 volunteers and lean polycystic ovary syndrome patients. *Neuroendocrinology* 2009;  
754 89:131-139.
- 755
- 756 Nunez-De La Mora A, Bentley GR, Choudhury OA, Napolitano DA and Chatterton RT.  
757 The impact of developmental conditions on adult salivary estradiol levels: why this  
758 differs from progesterone? *Am J Hum Biol* 2008; 20:2-14.
- 759
- 760 Nunez-de la Mora A, Chatterton RT, Choudhury OA, Napolitano DA and Bentley GR.  
761 Childhood conditions influence adult progesterone levels. *PLoS Med* 2007; 4:e167.
- 762 O'Rourke MT and Ellison PT. Salivary estradiol levels decrease with age in healthy,  
763 regularly-cycling women. *Endocr J* 1993; 1:487-494.
- 764
- 765 Oktay K, Newton H, Mullan J and Gosden RG. Development of human primordial  
766 follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone.  
767 *Hum Reprod* 1998; 13:1133-1138.
- 768
- 769 Richards JS, Russell DL, Ochsner S and Espey LL. Ovulation: new dimensions and new  
770 regulators of the Inflammatory-like response. *Annu Rev Physiol* 2002; 64:69-92.
- 771
- 772 Robertson DM, Hale GE, Jolley D, Fraser IS, Hughes CL and Burger HG.  
773 Interrelationships between ovarian and pituitary hormones in ovulatory menstrual cycles  
774 across reproductive age. *J Clin Endocrinol Metab* 2009; 94:138-144.
- 775
- 776 Santoro N, Lasley B, McConnell D, Allsworth J, Crawford S, Gold EB, Finkelstein JS,  
777 Greendale GA, Kelsey J, Korenman S et al. Body size and ethnicity are associated with  
778 menstrual cycle alterations in women in the early menopausal transition: The Study of  
779 Women's Health across the Nation (SWAN) Daily Hormone Study. *J Clin Endocrinol*  
780 *Metab* 2004; 89:2622-2631.
- 781
- 782 Strauss JF and Williams CJ. The ovarian life cycle. In Strauss JF and Barbieri RL (eds)  
783 Yen and Jaffe's *Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical*  
784 *Management*. 2004. Elsevier Saunders, Philadelphia, PA, pp. 213-254.
- 785

- 786 Treloar AE, Boynton RE, Behn BG and Brown BW. Variation of the human menstrual  
787 cycle through reproductive life. *Int J Fertil* 1967; 12:77-126.  
788
- 789 Venners SA, Liu X, Perry MJ, Korrick SA, Li Z, Yang F, Yang J, Lasley BL, Xu X and  
790 Wang X. Urinary estrogen and progesterone metabolite concentrations in menstrual  
791 cycles of fertile women with non-conception, early pregnancy loss or clinical pregnancy.  
792 *Hum Reprod* 2006; 21:2272-2280.  
793
- 794 Vollman RF. *The Menstrual Cycle*, 1977. Saunders, Philadelphia.  
795
- 796 Waller K, Swan SH, Windham GC, Fenster L, Elkin EP and Lasley BL. Use of urine  
797 biomarkers to evaluate menstrual function in healthy premenopausal women. *Am J*  
798 *Epidemiol* 1998; 147:1071-1080.  
799
- 800 Windham GC, Elkin E, Fenster L, Waller K, Anderson M, Mitchell PR, Lasley B and  
801 Swan SH. Ovarian hormones in premenopausal women: variation by demographic,  
802 reproductive and menstrual cycle characteristics. *Epidemiology* 2002; 13:675-684.  
803  
804